In line with these results, an improvement in oxidants/antioxidant balance, as evidenced by MDA, and TAC as well as histopathological findings is consistent with the effect of targeting NF-κB /NLRP3/ IL-1β pathway in the improvement of chronic renal diseases (Zhang and Wang 2019). The gene discussed is NLRP3; the disease is chronic kidney disease.